Stay updated on Flotetuzumab in Relapsed AML/MDS Post Allo-HCT Clinical Trial

Sign up to get notified when there's something new on the Flotetuzumab in Relapsed AML/MDS Post Allo-HCT Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Flotetuzumab in Relapsed AML/MDS Post Allo-HCT Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    9 days ago
    Change Detected
    Summary
    The web page has been updated from version v2.15.0 to v2.15.2.
    Difference
    0.3%
    Check dated 2025-05-01T05:52:12.000Z thumbnail image
  3. Check
    16 days ago
    No Change Detected
  4. Check
    23 days ago
    Change Detected
    Summary
    The page has been updated to reflect a new version, changing from v2.14.4 to v2.15.0.
    Difference
    1.0%
    Check dated 2025-04-16T15:02:25.000Z thumbnail image
  5. Check
    30 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.14.3 to version 2.14.4.
    Difference
    0.3%
    Check dated 2025-04-09T10:44:20.000Z thumbnail image
  6. Check
    74 days ago
    Change Detected
    Summary
    The page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.
    Difference
    5%
    Check dated 2025-02-24T22:05:21.000Z thumbnail image
  7. Check
    88 days ago
    Change Detected
    Summary
    The page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with a contact for assistance.
    Difference
    5%
    Check dated 2025-02-10T14:40:59.000Z thumbnail image
  8. Check
    95 days ago
    Change Detected
    Summary
    The website has been updated from version v2.14.1 to v2.14.2.
    Difference
    0.3%
    Check dated 2025-02-03T10:15:25.000Z thumbnail image

Stay in the know with updates to Flotetuzumab in Relapsed AML/MDS Post Allo-HCT Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Flotetuzumab in Relapsed AML/MDS Post Allo-HCT Clinical Trial page.